Skip to main content

Advertisement

SpringerLink
Log in

Growth factors and renal cancer: characterization and therapeutic implications

  • Published:
World Journal of Urology Aims and scope Submit manuscript

Summary

The heterogeneiety of renal-cell carcinoma can lead to unpredictable behavior: the ability to achieve a large volume yet not metastasize, the ability to demonstrate late recurrence or spontaneous regression, or the capability to metastasize at a relatively small volume. One-third of all patients who undergo radical nephrectomy for presumed localized disease will eventually have metastasis. Since renal-cell carcinoma is not significantly radio-or chemosensitive, it is important to investigate new avenues for treatment of this tumor once it has spread, specifically at the molecular level. This review discusses the most recent work on growth factors and renal cancer and proposes possible modalities for treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aulitzky W, Gastl G, Aulitzky WE, Herold M, Kemmler J, Mull B, Frick J, Huber C (1989) Successful treatment of metastatic renal cell carcinoma with a biologically active dose of γINF. J Clin Oncol 7:1875–1881

    Google Scholar 

  2. Belldegrun A, Pierce W, Kaboo R, Tso CL, Shau H, Turcillo P, Moldawer N, Golub S, de Kernion J, Figlis R (1993) Interferon-a primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-a as therapy for metastatic renal cell carcinoma. J Urol 150:1384–1389

    Google Scholar 

  3. Bosniak M (1993) Problems in the radiologic diagnosis of renal parechymal tumors. Urol Clin North Am 20:217–230

    Google Scholar 

  4. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA (1994) Predictors of pathologic stage in prostate carcinoma. The role of neovascularity. Cancer 73:678–687

    Google Scholar 

  5. Chang SY, Yu D, Sherwood ER, Kozlowski JM, Lee C (1992) Inhibitory effects of suramin on a human renal cell carcinoma line causing nephrogenic hepatic dysfunction. J Urol 147: 1147–1150

    Google Scholar 

  6. Chodak GW, Hospelhorn V, Judge SM (1988) Increased levels of fibroblast growth factor activity in urine from patients with bladder and kidney cancer. Cancer Res 48:2083–2088

    Google Scholar 

  7. Derynk R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman TS, Berger WH (1987) Synthesis of messenger RNA's for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 47:707–712

    CAS  PubMed  Google Scholar 

  8. Ellerhorst JA, Kilbourn RG, Amato RJ, Zukiwski AA, Jones E, Logothetis CJ (1994) Phase II trial of low dose γ-interferon in metastatic renal cell carcinoma. J Urol 152:841–845

    Google Scholar 

  9. Erlandson R, Bergerheim USR, Boldog F (1990) A gene near the D3F15S2 site on 3p is expressed in normal human kidney but not or only at a severely reduced level in 10 of 15 primary renal cell carcinomas. Oncogene 5:1207–1211

    Google Scholar 

  10. Folkman J (1976) The vascularization of tumors. Sci Am 234:58–68

    Google Scholar 

  11. Folkman J (1982) Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175:409–414

    Google Scholar 

  12. Fox SB, Leek RD, Smith K, Hollyer J, Greenall M, Harris AL (1994) Tumor angiogenesis in node negative breast carcinoma — relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat 29:109–116

    Google Scholar 

  13. Gansler T, Vaghmur N, Olson JJ, Graham SD (1992) Suramin inhibits growth factor binding and proliferation of urothelial carcinoma cell cultures. J Urol 148:910–914

    Google Scholar 

  14. Gomella LG, Sargent ER, Wade TP (1989) Expression of transforming growth factor alpha (TGFa) in normal human kidney and enhanced expression of transforming growth factors alpha and beta in renal cell carcinoma. Cancer Res 49:6972–6975

    CAS  PubMed  Google Scholar 

  15. Gospodarowicz D, Neufield G, Schweigerer L (1986) Fibroblast growth factor: a review. Mol Cell Endocrinol 46:187–201

    Google Scholar 

  16. Harris RH, Hise K, Best CF (1983) Renotropic factors in urine. Kidney Int 23:616–623

    Google Scholar 

  17. Kerbel RS (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents: a review. Bioassays 13:31–36

    Google Scholar 

  18. Klotz LH, Kulkarni C, Mills G (1991) End stage renal disease serum contains a specific renal cell growth factor. J Urol 145:156–160

    Google Scholar 

  19. Kochevar J (1990) Blockage of autonomous growth of ACHN cells by anti-renal cell carcinoma monoclonal antibody 5F4. Cancer Res 50:2968–2972

    Google Scholar 

  20. Kochevar GJ, Stanek JA, Rucker EB (1992) Truncated fibronectin: an autologous growth-promoting substance secreted by renal carcinoma cells. Cancer 69:2311–2315

    Google Scholar 

  21. Koo AS, Armstrong C, Bochner B (1992) Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother 35:97–105

    Google Scholar 

  22. Laforgia S, Laota J, Latif F, Boghosian-Sell L, Kastury K, Ohta M, Druck T, Atchison L, Cannizzaro LA, Barnea G (1993) Detailed genetic and physical map of the 3p chromosome region surrounding the familial renal cell carcinoma chromosome translocation, t(3;8) (p14.2;q24.1). Cancer Res 53:3118–3124

    Google Scholar 

  23. LaRocca RV, Stein CA, Danesi R, Cooper MR, Uhrich M, Myers CE (1991) A pilot study of suramin in the treatment of metastatic renal cell carcinoma. Cancer 67:1509–1513

    Google Scholar 

  24. Linehan WM, Shipley WU, Longa DL (1989) Cancer of the kidney and ureter. In: De Vita VT, Hellman S, Rosenberg S (eds) Cancer, principles and practice of oncology, 3rd edn. J. B. Lippincott, Philadelphia, pp 979–1007

    Google Scholar 

  25. Malt RA (1969) Compensatory growth of the kidney. N Engl J Med 280:1446–1458

    Google Scholar 

  26. Masui H, Kawamoto T, Sato JD, Wolf B, Sato B, Mendelsohn J (1984) Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44:1002–1007

    Google Scholar 

  27. Motzer RJ, Nanus DM, O'Moore P, Scher HI, Bajorin DF, Reuter V, Tong WP, Iversen J, Lousinson C, Albino AP, Bosl G (1992) Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res 52:5775–5779

    Google Scholar 

  28. Mydlo JH, Bard R (1987) An analysis of papillary adenocarcinoma of the kidney. Urology 30:529–534

    Google Scholar 

  29. Mydlo JH, Fair WR (1988) Growth factors and angiogenesis in urology. (AUA Update Series, vol 7, lesson 39) American Urological Association Office of Education, Houston, Texas

    Google Scholar 

  30. Mydlo JH, Macchia RJ (1992) Growth factors in urology: detection, characterization and clinical applications. Urology 40:491–498

    Google Scholar 

  31. Mydlo JH, Bard RH, Freed SZ (1986) Detection of tumor angiogenesis factor in adenocarcinoma of the kidney. Urology 27:447–450

    Google Scholar 

  32. Mydlo JH, Heston WDW, Fair WR (1988) Characterization of a heparin-binding growth factor from adenocarcinoma of the kidney. J Urol 140:1575–1579

    Google Scholar 

  33. Mydlo JH, Michaeli J, Goldenberg A, Heston WDW, Fair WR (1989) Expression of transforming growth factor alpha and epidermal growth factor receptor mRNA in neoplastic and nonneoplastic renal tissue. Cancer Res 49:3407–3411

    Google Scholar 

  34. Mydlo JH, Zajac J, Macchia RJ (1993) Conditioned media from a renal carcinoma cell line demonstrates the presence of basic fibroblast growth factor. J Urol 150:997–1001

    Google Scholar 

  35. Nakamoto T, Usua A, Oshima K (1988) Analysis of growth factors in renal cell carcinoma. Biochem Biophys Res Commun 153:818–824

    Google Scholar 

  36. Nanus DM, Schmitz-Drager BJ, Motzer RJ, Lee AC, Vlamis V, Cordon-Cardo C, Albino AP, Reuter VE (1993) Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 85:1597–1599

    Google Scholar 

  37. Neal DE, Sharples L, Smith K, Fenelly J, Hall RR, Harris AL (1990) The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65:1619–1625

    Google Scholar 

  38. Nguyen NM, Lehr JE, Pienta KJ (1993) Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo. Anticancer Res 13:2143–2147

    Google Scholar 

  39. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J (1994) Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 86:356–360

    Google Scholar 

  40. Nishimura N, Kanda S, Yogi Y, Kawamura M, Nakamura M, Hyakutake H, Kanetake H, Saito Y (1992) Secretion of autocrine growth-promoting activity by renal carcinoma cells treated with 5-fluorouracil. Int J Cancer 52:105–109

    Google Scholar 

  41. Okamoto T, Fujioka T, Horiuchi S (1991) A study of the metabolism of vitamin D in patients with renal cell carcinoma — with special reference to serum concentrations of 1 alpha, 25-(OH)2D and its clinical significance. Jpn J Urol 82:890–899

    Google Scholar 

  42. Peehl DW, Wong ST, Stamey TA (1991) Cytostatic effects of suramin on prostate cancer cells cultured from primary tumors. J Urol 145:624–630

    Google Scholar 

  43. Pienta KJ, Isaacs WB, Vindivich D, Coffey DS (1991) The effects of basic FGF and suramin on cell motility and growth of rat prostate cancer cells. J Urol 145:199–202

    Google Scholar 

  44. Quesada JR, Kurzrock R, Sherwin SA, Gutterman JU (1987) Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J Biol Response Modifiers 6:20–25

    Google Scholar 

  45. Sargent ER, Gomella LG, Belldegrun A, Linehan WM, Kasid A (1989) Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma. J Urol 142:1364–1368

    Google Scholar 

  46. Scher HI, Heston WDW (1992) Suramin as an archetypical compound in the development of growth factor antagonists for inhibition of genitourinary tumors (review). Cancer Treat Res 59:131–151

    Google Scholar 

  47. Sklar GN, Eddy H, Jacobs SC, Kyprianou N (1993) Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis. J Urol 150:1526–1532

    Google Scholar 

  48. Stadler W, Vogelzang NJ (1993) Human renal cancer carcinogenesis: a review of recent advances. Ann Oncol 4:451–462

    Google Scholar 

  49. Stadler WM, Richards JM, Vogelzang NJ (1992) Serum interleukin-6 levels in metastatic renal cell carcinoma: correlation with survival but not an independent prognostic indicator. J Natl Cancer Inst 84:1835–1836

    Google Scholar 

  50. Taide M, Kanda S, Eguchi J, Igawa T, Kanetke H, Saito Y (1993) A study of growth factors in human renal cysts with or without renal cell carcinoma. Clin Chim Acta 217:199–203

    Google Scholar 

  51. Tosaka A, Ohya K, Yamada K, Ohashi H, Kitahara S, Sekine H, Takehara Y, Oka K (1990) Incidence and properties of renal masses and asymptomatic renal cell carcinoma detected by abdominal ultrasonography. J Urol 144:1097–1101

    Google Scholar 

  52. Von Eschenbach AC, Avallone A, Price J, Swanson D, Killion J, Stephenson R, Fidler IJ (1990) The biology of renal cancer. Eur Urol 18:40–41

    Google Scholar 

  53. Wade TP, Kasid A, Stein CA, La Rocca RV, Sargent ER, Gomella LG, Myers CE, Linehan WM (1992) Suramin interference with transforming growth factor beta inhibition of human renal cell carcinoma in culture. J Surg Res 53:195–198

    Google Scholar 

  54. Watanabe H, Hori A, Seno M (1991) A sensitive enzyme immunoassay for human basic fibroblast growth factor. Biochem Biophys Res Commun 175:229–235

    Google Scholar 

  55. Wynder EL, Mabuschi K, Whitmore WF Jr (1974) Epidemiology of adenocarcinoma of the kidney. J Natl Cancer Inst 53:1619–1630

    Google Scholar 

  56. Yamamoto N, Kanetake H, Yamada J (1983) In vitro evidence from tissue cultures to prove existence of rabbit and human renotrophic growth factor. Kidney Int 23:624–631

    Google Scholar 

  57. Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T (1993) Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone independent human breast and prostate cancer cell lines. Cancer Res 53:5233–5236

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, State University of New York Health Science Center at Brooklyn, 450 Clarkson Avenue, Box 79, 11203, Brooklyn, NY, USA

    J. H. Mydlo

Authors
  1. J. H. Mydlo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mydlo, J.H. Growth factors and renal cancer: characterization and therapeutic implications. World J Urol 13, 356–363 (1995). https://doi.org/10.1007/BF00191217

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00191217

Keywords

Search

Navigation